Prevalence of ATP7B Gene Mutations in Iranian Patients With Wilson Disease

Narges Zali 1, Seyed Reza Mohebbi 1, Sahar Esteghamat 1, Mohsen Chiani 1, Mahdi Montazer Haghighi 1, Seyed Mohammad-Kazem Hosseini-Asl 1, Faramarz Derakhshan 1, Amir-Hosseang Mohammad-Alizadeh 1, Seyed-Ali Malek-Hosseini 1, Mohammad Reza Zali 1

1 Research Centre for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

Article type: Original Article

Article history:
Received: 26 Jun 2011
Revised: 02 Aug 2011
Accepted: 25 Aug 2011

Keywords:
Wilson Disease Protein
Mutation
ATP7B Protein

ARTICLE INFO

ABSTRACT

Background: Wilson disease (WD) is an autosomal recessive disorder. The WD gene, ATP7B, encodes a copper-transporting ATPase involved in the transport of copper into the plasma protein ceruloplasmin and in excretion of copper from the liver. ATP7B mutations cause copper to accumulate in the liver and brain.

Objectives: We examined the ATP7B mutation spectrum in Wilson disease patients in Iran.

Patients and Methods: Genomic DNA was extracted from patients with Wilson disease. The entire coding region of the ATP7B gene was amplified using PCR and analyzed using direct sequencing.

Results: We identified five novel mutations in 5 Iranian patients with Wilson disease. The first was a transversion, c.2363C > T, which led to an amino acid change from threonine to isoleucine. The second mutation was a deletion, c.2532delA (Val845Ser), which occurred in exon 10. The third mutation was a transition mutation, c.2311C > G (Leu770Leu), which occurred in the TM4 domain of the ATP7B protein. The fourth mutation was a transversion, (c.3061G > A) (Lys1020Lys), in exon 14. Lastly, we identified a transversion, c.3206C > A (His1069Asn) in exon 14 which led to a change in function of the ATP loop domain of the ATP7B protein. The H1069Q mutation was identified as the most common mutation in our study population.

Conclusions: Based on our findings, the H1069Q may be a biomarker that can be used in a rapid detection assay for diagnosing WD patients.

Implication for health policy/practice/research/medical education: Although a variety of mutations have been identified in the ATP7 gene in Wilson disease patients around the world, there is not enough data about it in Iranian patients. This study will provide valuable information about mutational hot spot regions of ATP7B gene in Iranian patients for the first time and may help researchers to develop specific diagnostic tests for our population. We highly recommend biologists and Gastroenterologists to study this article.

Please cite this paper as:
Zali N, Mohebbi SR, Esteghamat S, Chiani M, Montazer Haghighi M, Hosseini-Asl SM, et al. Prevalence of ATP7B Gene Mutations in Iranian Patients With Wilson Disease. Hepat Mon. 2011;11(11):890-4. DOI: 10.5812/kowsar.1735143X.762

1. Background

Wilson disease (WD, MIM #277900) is an autosomal re-

cessive disorder of copper metabolism resulting in toxic copper accumulation in the liver and other organs such as the brain, kidney, and cornea. Clinically, increased copper in cells can result in hepatic cirrhosis and neurological damage. The prevalence of WD varies from 1/30,000 to 1/100,000 in different populations, with an estimated carrier rate of 1 in 90 (1, 2). The WD gene, which maps to chromosome 13q14.3, encodes a 165 kDa copper-trans-
porting P-type ATPase, ATP7B (MIM #606882) (3). ATP7B
ATP7B Gene Mutations and Wilson Disease

Zali N et al.

The ATP7B gene consists of 21 exons spanning a genomic region of approximately 80 kb. The protein is made up of 1465 amino acids and is predominantly expressed in the liver, with reduced expression in the brain, kidney, and placenta (4-6). ATP7B has several membrane-spanning domains, including 6 copper binding domains, 8 transmembrane domains (Tm), a transduction domain that uses energy from ATP hydrolysis for cation transport, a Tm cation domain, and a phosphorylation domain (7, 8). ATP7B mutations result in copper accumulation in the liver and brain, resulting in clinical manifestations such as liver disease, hemolysis, renal alterations, and neuropsychiatric disease. Kayser-Fleischer (KF) rings in the periphery of the cornea and copper abnormalities in serum and urinary tests are frequently observed (9, 10). More than 270 different mutations have been identified in the ATP7B gene along the length of the coding region as well as in the promoter (11).

2. Objectives

The aim of this study was to identify mutations in a large group of Iranian patients with WD. This is the first comprehensive mutation analysis of the Iranian population.

3. Patients and Methods

A total of 70 WD patients, 40 males and 30 females, ranging in age from 5–40 years from 54 families were included in the study. Patients were diagnosed based on clinical symptoms. Hepatic patients showed liver involvement. Neurological patients showed neurological symptoms such as tremor, clumsiness, dysarthria, and ataxia in addition to Dystonic-Parkinsonian Syndrome. Mixed-type patients were diagnosed based on liver involvement and neurological features. Criteria for diagnosing patients with WD included serum ceruloplasmin levels of 20 mg/dL, urine copper > 40 mmol/24 h, liver copper > 250 μg/g dry weight, and the presence of Kayser-Fleischer (K-F) rings. Patients who fulfilled 2 of these criteria were included in the study. Patients who were positive for hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBCAb), or had acute hepatitis or malignant tumors were excluded. This investigation was approved by the local Research Center for Gastroenterology and Liver Diseases (RCGLD) ethics committee and appropriate informed consent was obtained from all patients and their families.

3.1. Polymerase Chain Reaction and Sequencing

DNA was extracted from whole blood using standard phenol-chloroform extraction (12). ATP7B gene exons were amplified using PCR; 35 cycles, including a 30-s denaturing step at 94°C, a 30-s annealing step at the appropriate temperature, and a 35-s extension step at 72°C, were used for amplification. The reaction mixture contained 100 ng genomic DNA as the template, 19.4 μL dH2O, 0.5 μL 10 mM dNTP, 0.75 μL 50 mM MgCl2, 12.5 pM of each primer, and 1 unit of Taq DNA polymerase (Gibco BRL, Invitrogen, Carlsbad, CA, USA) in a total volume of 25 μL. Primers were designed using Gene Runner and Primer3 software. Bi-directional PCR-sequencing was carried out using the ABI 3130xl Genetic Analyzer (Applied-Biosystems, Foster City, CA, USA). Sequences were aligned and analyzed using ClustalX2 and BioEdit software, respectively. To detect novel mutations and polymorphisms in the gene, 50 control samples were compared with samples from diseased patients. Changes were classified as polymorphisms if they did not change the amino acid sequence or when they were also detected in normal chromosomes. Based on mutations recorded at http://www.HGMD.org/, the detected mutations were named using the sequence with the GenBank accession number NM_00053.1 as a reference.

4. Results

The clinical characteristics of 70 patients with WD were evaluated. Of the 70 patients, 21 (22.8%) had at least 1 mutation. Among the 21 patients with mutations, age at diagnosis ranged from 7 to 25 years (Table 1). A total of 21 different mutations were identified. According to recent publications and the “Wilson disease mutation database” (http://www.uofa-medical-genetics.org/wilson/index.html), we identified 5 novel mutations that affect various protein domains of the ATP7B gene;
these mutations include c.2363C > T, c.2532delA, c.2311C > G, c.3061G > A, and c.3206C > A (Table 2, Figure 1).

Table 3 shows that a novel substitution in exon 9 involving the protein transmembrane domain at Thr787Ile was identified in 2 homozygous patients who were 23- and 28-year-old sisters; interestingly, the older sister (28 years) exhibited only neurologic manifestations, while the younger (23 years) presented with acute hepatic failure and had undergone liver transplantation. Both exhibited the KF ring. The second novel mutation identified in this study was a deletion in exon 10 (c.2532delA) in a 9-year-old girl presenting with hepatic failure and neurologic features. She also showed the KF ring. The third novel mutation, 2311C > G, was identified in a 22-year-old man, who demonstrated hepatic and neurologic features accompanied by the KF ring. The fourth novel mutation, c.3061G > A, was a silent mutation identified in exon 14. This mutation was found in a 14-year-old boy.
who also exhibited the KF ring. The fifth novel mutation, c.3206C > A, was detected in a hot spot region of exon 14. It was detected in a 21-year-old girl presenting with acute hepatic failure and neurological manifestations. Additionally, she exhibited the KF ring. A total of 20 (28.6%) patients with mutations were homozygous, while one patient (1.4%) had a compound heterozygous mutation. The most commonly observed mutation was the H1069Q point mutation in 4 of 21 patients (19%), all of whom were homozygous. Interestingly, the D642H mutation was detected in members of the same family. This mutation resulted in both hepatic and neurological symptoms. Two sisters with hepatic WD were heterozygous for this mutation, while their brother was homozygous for D642H. He exhibited neurological symptoms of WD. Thus, the D642H mutation has been detected in one family and exhibited both hepatic and mixed WD presentations.

Table 2 summarizes the mutations identified and corresponding ages at disease onset, presence of the KF ring, and involvement of the liver, brain, or both. In addition to the 21 different mutations, 6 different sequence variations with no clinical significance were identified (Table 4). These variants were identified in previous studies as polymorphisms detected in a normal population or as those not altering amino acid composition of the protein. To clarify whether these nucleotide and amino acid sequence changes were mutations or polymorphisms, we analyzed 50 normal individuals using direct sequencing of their PCR products.

5. Discussion

In this study, we examined the mutation spectrum of the ATP7B gene among the Iranian population. We identified 21 different mutations, including 5 novel, disease-causing mutations in 21 individuals in 70 referred patients, reflecting the genetic heterogeneity of Wilson disease. Population-frequency values of these mutations revealed that the spectrum of WD mutations consists of a large number of rare mutations. Six single nucleotide polymorphisms (SNPs) were identified (Table 4). An interesting case of marked clinical heterogeneity within a single family included 2 sisters with the homozygous T787I mutation. One exhibited only neurological manifestations, while the other presented with acute hepatic failure and had undergone liver transplantation. This considerable phenotypic variation for the same genotype suggests involvement of additional genetic, epigenetic, or even environmental factors in the pathogenesis of Wilson disease. The pathogenicity of the novel missense mutation T787I was evaluated for 3 primary factors. First, segregation analysis was performed using variable SNPs within the ATP7B gene in this family, which confirmed the presence of a mutation in the ATP7B gene responsible for causing WD. Second, T787I was not detected among 50 unrelated control subjects screened. Third, a mutation is presumed to be pathologic when it is located in the conserved region of a gene. However, the change in a hydrophilic amino acid, threonine, to a non-polar hydrophobic amino acid, isoleucine, in a conserved transmembrane domain of a protein can change its function. Further investigation is necessary to elucidate the details of this abnormal function. The most frequently observed mutation in the ATP7B gene responsible for causing WD in the U.S. and in central Europe is H1069Q, which is located in exon 14. For instance, this mutation occurs at frequencies of 61% among Austrian, 39% among Russian, 38% among North American and Swedish, 34% among Dutch, 28% among Canadian, 17% among Turkish, and 12% among Italian Wilson patients. It is associated with CNS diseases and a later onset of disease (5, 13, 14). However, we observed this mutation in four (19%) patients, all of whom had only hepatic symptoms and were 5–40 years of age. This mutation disrupts the unique SEHPL amino acid motif and leads to a deficiency in ATP binding (6).

The 5 novel mutations included missense, silent, and deletion mutations. One was a novel causative mutation, H1069N. We screened 50 unrelated individuals for this mutation; none of the tested subjects was a heterozygote or a homozygote. The H1069N mutation occurs in a conserved region, and involves the conversion of the non-polar amino acid histidine to the hydrophilic amino acid asparagine within the highly-conserved SEHPL domain; alterations in this region are highly deleterious (15, 16). The Thr787Ile substitution replaces a polar residue with a non-polar and hydrophobic amino acid. This mutation is expected to change the function of the transmembrane domain by altering secondary structure. The c.2532delA is a deletion of a nucleotide (A) in exon 10; however, this mutation is silent.

Mutations 2311C > G and 3060G > A were also silent; thus, no alteration in amino acid sequence was observed. R778L is one of the most prevalent mutations in Eastern Asian patients and leads to liver involvement in WD patients (17-20). We observed this mutation in a compound heterozygous state with R969Q in 1 patient with hepatic

| SNP             | Exon | Frequency in Cases | Frequency in Controls |
|-----------------|------|--------------------|-----------------------|
| T1216G (A405S) | 2    | 0.30               | 0.32                  |
| G1567C (I456V) | 3    | 0.23               | 0.35                  |
| A2495G (K831R) | 10   | 0.31               | 0.38                  |
| G2855A (K952R) | 12   | 0.26               | 0.31                  |
| G3009A (A1003A)| 13   | 0.1                | 0.15                  |
| G2973A (T991T) | 13   | 0.05               | 0.08                  |

ATP7B Gene Mutations and Wilson Disease

Zali N et al.
failure. This finding may be related to the mixed ethnic background of the Iranian population. H1069Q is the most commonly observed mutation responsible for WD in our patients. This finding highlights the importance of ATP7B mutation screening in high-risk consanguineous marriages. The significance of the various mutations remains to be elucidated, and we could not identify clear genotype-phenotype associations; thus, further studies are needed. In conclusion, although mutations were distributed among different exons of the ATP7B gene in Iranian patients with WD, 6 of 21 mutations were located in exon 14. Therefore, this exon may be a mutational hot spot in the Iranian population. This finding is compatible with the results from Western countries and in contrast with results from China. Hot spot exons reported in Western countries were 14 and 18, while the hot spot exons reported in China were 8 and 12 (20). These results are important for establishing a rapid and accurate mutation analysis method for diagnosing WD patients in the Iranian population.

Acknowledgments
The authors would like to express their gratitude to Masoumeh Soltani, Behzad Damavand, and the Department of Liver Transplantation at the Namaz Hospital in Shiraz for providing patient data.

Financial Disclosure
None declared.

Funding/Support
None declared.

References
1. Figus A, Angius A, Loudianos G, Bertini C, Desvi V, Loi A, et al. Molecular pathology and haplotype analysis of Wilson disease in Mediterranean populations. Am J Hum Genet. 1995;57(6):1318.
2. Margarit E, Bach V, Gomez D, Bruguer M, Jara P, Queralt R, et al. Mutation analysis of Wilson disease in the Spanish population—identification of a prevalent substitution and eight novel mutations in the ATP7B gene. Clin Genet. 2005;68(1):164-8.
3. Tanzi R, Petrukhin K, Chernov I, Pellequer J, Wasco W, Ross B, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993;5(3):344-50.
4. Bull PC, Cox DW. Long range restriction mapping of 130kb 3 focused on the Wilson disease region. Genomics. 1993;16(3):393-8.
5. Duc H, Hetter H, Stremmel W, Castañeda-Guillot C, Hernández HA, Cox DW, et al. His1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype.

Eur J Hum Genet. 1998;6(6):616.
6. Vrabelova S, Letocha O, Borovy M, Kozak L. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. Mol Genet Metab. 2005;86(1-2):277-85.
7. Degutti MM, Genschel J, Canocado ELR, Barbosa ER, Bochow B, Mucenic M, et al. Wilson disease: novel mutations in the ATP7B gene and clinical correlation in Brazilian patients. Hum Mutat. 2004;23(4):398.
8. Petrukhin K, Lutsenko S, Chernov I, Ross BM, Kaplan JH, Gilliam TC. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. Hum Mol Genet. 1994;3(9):1647.
9. Das M, Misra U, Kalita J. A study of clinical, MRI and multimodal- ity evoked potentials in neurologic Wilson disease. Eur J Neurol. 2007;14(5):498-504.
10. Gromadzka G, Schmidt HH, Genschel J, Bochow B, Rodo M, Tar- nacka B, et al. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease. Mov Disord. 2006;21(2):245-8.
11. Park S, Park YJ, Kim GH, Choi JH, Kim RM, Kim JR, et al. Identifi- cation of novel ATP7B gene mutations and their functional roles in Korean patients with Wilson disease. Hum Mutat. 2007;28(11):1088-91.
12. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press; 2001.
13. Caca K, Ferenci P, Kühn HJ, Polli C, Willgerodt H, Kunath B, et al. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol. 2003;39(5):579-81.
14. Payne AS, Kelly EJ, Gutin JD. Functional expression of the Wilson disease protein reveals mislocalization and impaired copper-dependent trafficking of the common H1069Q mutation. Proc Natl Acad Sci U S A. 1998;95(38):20854-9.
15. Gromadzka G, Schmidt HH, Genschel J, Bochow B, Rodo M, Tar- nacka B, et al. Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease. Clin Genet. 2005;68(5):524-32.
16. Morgan CT, Tsivkovskii R, Kosinskava YA, Efremov RG, Lutsenko S. The distinct functional properties of the nucleotide-binding domain of ATP7B, the human copper-transporting ATPase. Analysis of the Wilson disease mutations T1064A, H1069Q, R153H, and C104F. J Biol Chem. 2004;279(35):36363-71.
17. Kim EK, Yoo OJ, Song KY, Yoo HW, Choi SY, Cho SW, et al. Identification of three novel mutations and a high frequency of the Arg778Leu mutation in Korean patients with Wilson disease. Hum Mutat. 1999;18(4):275-8.
18. Kusuda Y, Hamaguchi K, Mori T, Shin R, Seike M, Sakata T. Novel mutations of the ATP7B gene in Japanese patients with Wilson disease. J Hum Genet. 2000;45(2):86-91.
19. Shah AB, Chernov I, Zhang HT, Ross BM, Das K, Lutsenko S, et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet. 1997;61(2):377-28.
20. Zhiying W, Ning W, Shenxing M. Identification and analysis of mutations of the Wilson disease gene in Chinese population. Chin Med J (Engl). 2000;113(1):40-3.